

1 **Original research**

2 **Genetically Predicted Blood Metabolites Mediate the Association**
3 **Between Gut Microbiota and Childhood with obesity: A Mendelian**
4 **Randomization Study**

5 **Min Zhang¹, Wenjuan Yan²**

6 1. Department of Preventive Healthcare, Datuan Community Health Service Center, Pudong
7 New District, Shanghai, China

8 2. Department of Functional Medicine, Guangming Hospital of Traditional Chinese Medicine,
9 Pudong New District, Shanghai, China

10 **Correspondence**

11 Wenjuan Yan. Department of Medical Functional Examination, Guangming Hospital of
12 Traditional Chinese Medicine, 43 Dongmen Street, Pudong New District, Shanghai
13 201399, China, Email: zhm395010878@gmail.com

14 **ORCID**

15 <https://orcid.org/0009-0002-6879-9106>

16 **Summary**

17 **Background:** Childhood with obesity is characterized by metabolic dysregulation and
18 unique gut microbiota profiles. Nevertheless, the comprehensive understanding of gut
19 microbiota and metabolic dysregulation of Childhood with obesity remains unclear.

20 **Objectives:** This study aimed to investigate the causal relationship of gut microbiota and
21 Childhood with obesity and identify the blood metabolites as potential mediators.

22 **Methods:** The exposure genome-wide association studies (GWAS) data were sourced
23 from the GWAS Catalog, while the outcome GWAS data were obtained from the Early
24 Growth Genetics (EGG) Consortium. The study used 473 types of gut microbiota, 233
25 types of blood metabolites, and Childhood with obesity from GWAS. We then performed
26 two-sample Mendelian randomization (TSMR) and bidirectional Mendelian randomization
27 (BDMR) analyses to explore the causal relationships between gut microbiota, blood
28 metabolites, and Childhood with obesity. Additionally, we conducted multivariable
29 Mendelian randomization (MVMR) and two-step Mendelian randomization (2SMR) to
30 identify potential mediating blood metabolites in this process.

31 **Results:** MR analysis identified 13 types of gut microbiota and 12 types of blood
32 metabolites that were causally associated with Childhood with obesity. Furthermore,
33 there was no strong evidence that genetically predicted Childhood with obesity had an
34 effect on these gut microbiota and blood metabolites. Further, 2SMR analysis revealed
35 that the association between K10 sp001941205 and Childhood with obesity was
36 mediated by the Total cholesterol to total lipids ratio in medium VLDL, accounting for 2.53%
37 (95%CI; 2.14%-2.92%) of the association. Similarly, the relationship between SM23-33
38 and Childhood with obesity was mediated by the Ratio of 22:6 docosaehaenoic acid to
39 total fatty acids, which accounted for 4.07% (95%CI; 2.70%-5.44%) of the association.

40 **Conclusions:** The present study is the first to investigate the causal relationships among
41 473 gut microbiota phenotypes, 233 blood metabolites, and Childhood with obesity
42 through Mendelian randomization analysis, identifying 13 gut microbiota types with

43 potential causal links to Childhood with obesity and suggesting that 2 blood metabolites
44 may mediate these associations, thereby providing valuable insights for future
45 intervention strategies aimed at addressing Childhood with obesity.

46 **Keywords**

47 gut microbiota, blood metabolites, mendelian randomization, Childhood with obesity

48 **1 Introduction**

49 Obesity is a long-term and complex condition where having too much body fat can
50 seriously harm children's health¹⁻². It can lead to a higher risk of type 2 diabetes³, and
51 heart disease⁴, impact bone health,⁵ and reproductive functions,⁶ and even increase the
52 likelihood of certain cancers⁷. Additionally, obesity can affect everyday activities like
53 sleeping well and moving around comfortably.⁸ According to the latest figures from the
54 World Health Organization, in 2022, approximately one in eight people worldwide was
55 living with obesity. Since 1990, adult obesity rates have more than doubled, and the rates
56 among teenagers have quadrupled. By 2022, there were over 390 million children and
57 adolescents aged 5 to 19 years who were overweight, including 160 million classified as
58 obese. Reducing the projected prevalence of overweight and obesity by 5% annually
59 from current trends or maintaining it at 2019 levels would result in global economic
60 savings of approximately US\$29 billion or US\$201 billion per year, respectively, between
61 2020 and 2060.⁹ These statistics highlight the severity of the obesity epidemic and
62 underscore the urgent need for effective strategies to combat this global health crisis.

63 The gut microbiota is crucial for digestion,¹⁰ immune regulation,¹¹ and metabolism.¹²
64 A healthy gut microbiota is characterized by high diversity and stability;¹³ however, in
65 obese children, microbial diversity is often lower.¹⁴ Dysbiosis of the gut microbiota may
66 also trigger low-grade chronic inflammation, which is closely linked to insulin resistance
67 and metabolic syndrome. These metabolic disorders further exacerbate the problem of
68 obesity. Certain gut bacteria can enhance the host's energy absorption. For example, the
69 relative abundance of Firmicutes and Bacteroidetes is often more prevalent in obese
70 children, suggesting that these microbial groups may promote fat accumulation by
71 enhancing energy absorption efficiency in the host.¹⁵ The gut microbiota produces
72 metabolites through various metabolic pathways, and these metabolites can enter the
73 circulatory system and have widespread effects on the host's metabolism. Short-chain
74 fatty acids (SCFAs), such as acetate, propionate, and butyrate, produced by the
75 fermentation of dietary fiber by gut microbiota, can regulate energy metabolism, lipid
76 metabolism, and glucose metabolism. SCFAs affect the host's metabolic health through
77 binding to G protein-coupled receptors (such as GPR41 and GPR43).¹⁶ Metabolites of
78 the gut microbiota, such as lipopolysaccharides (LPS), are strong inflammatory mediators.
79 LPS can enter the circulatory system by disrupting the intestinal barrier, triggering
80 systemic inflammation, and thus promoting the onset of obesity-related metabolic
81 diseases.¹⁷

82 Studying the relationship between Childhood with obesity, gut microbiota, and
83 circulating metabolites is crucial for gaining a deeper understanding of the mechanisms
84 underlying obesity, providing new perspectives for its prevention and treatment. Exploring
85 the roles of gut microbiota and metabolites in obesity can offer a basis for developing

86 new intervention strategies¹⁸. For example, regulating gut microbiota through probiotics
87 and prebiotics may become an effective method for controlling Childhood with obesity.¹⁹
88 The involvement of gut microbiota and circulating metabolites in the onset and
89 progression of Childhood with obesity is a complex and multifaceted process. An in-depth
90 investigation of these mechanisms will not only help to understand the nature of obesity
91 but also provide scientific evidence and new strategies for its prevention and treatment.
92 While some progress has been made in research on the relationship between gut
93 microbiota and Childhood with obesity, there are still significant gaps and pressing
94 questions that need to be clarified. Many studies have found an association between gut
95 microbiota and obesity,²⁰ but in certain cases, the causal relationship remains unclear,
96 particularly regarding whether changes in gut microbiota are a cause or a consequence
97 of obesity in children.²¹ The composition of gut microbiota is highly complex, and some
98 important but less abundant strains may be overlooked, necessitating more precise
99 techniques to fully understand these symbiotic microorganisms. Additionally, gut
100 microbiota exhibit significant individual variability, leading to substantial differences in
101 microbial function and metabolic products among different individuals, which may limit
102 the applicability of research findings.²²

103 Mendelian randomization (MR) analysis is a robust epidemiological research
104 strategy based on Mendelian inheritance. This technique allows for estimating causal
105 relationships using genetic variants as instrumental variables, thereby addressing
106 confounding variables, measurement errors, and reverse causation.²³ We applied three
107 large-scale genome-wide association studies (GWAS) to study the relationship between
108 473 gut microbiota and 233 blood metabolites and Childhood with obesity using MR. The
109 aim is to elucidate the causal relationship between gut microbiota, blood metabolites, and
110 Childhood with obesity, and to gain a clearer understanding of how gut microbiota affects
111 Childhood with obesity through its effects on blood metabolites.

112 **2 Materials and Methods**

113 **2.1 Study design**

114 In this study, we employed a range of Mendelian Randomization (MR) methodologies,
115 including two-sample MR (TSMR), bidirectional MR (BDMR), multivariable MR (MVMR),
116 and two-step MR (2SMR), to investigate the causal relationships between gut microbiota,
117 blood metabolites, and Childhood with obesity. By employing BDMR, we avoid the
118 potential for reverse causation, ensuring that our findings accurately reflect the
119 directionality of the relationships. We utilized MVMR to minimize bias and obtain reliable
120 estimates of modifiable exposures and their relationships with targeted outcomes.

121 Our study design is based on three key assumptions essential for the causal
122 interpretation of MR estimates.²⁴ We ensured the reliability of our findings by using
123 genetic variations or single nucleotide polymorphisms (SNPs) as instrumental variables
124 (IVs) that meet three crucial criteria: (i) the genetic IVs are strongly associated with
125 exposure, (ii) the genetic IVs are not associated with confounders linked to the selected
126 exposure and outcome, and (iii) the genetic IVs influence the outcome only through the
127 exposure.²⁵ Additionally, we completed the STROBE-MR checklist to ensure the integrity

128 of this observational MR study;²⁶ relevant details are provided in [Supplementary Table S1](#),
129 and a clear overview of our study design is presented in [Figure 1](#).

130 2.2 Data sources

131 Gut microbiota association studies (GWAS) data utilized in this research were obtained fr
132 om a study of the genetic characteristics of gut microbiota. The original GWAS was cond
133 ucted on 2,801 microbial taxa and 7,967,866 human genetic variants from 5,959 individu
134 als enrolled in the FR02 cohort. GWAS summary data for Gut microbiota was downloade
135 d from the GWAS Catalog (https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/),
136 and the GWAS Catalog accession numbers range from [GCST90032172 to GCST90032](#)
137 [644](#). More detailed information about the GWAS data can be obtained from their study.²⁷

138 The GWAS data for blood metabolites were sourced from the GWAS Catalog,
139 originally generated by Karjalainen MK et al.,²⁸ with GWAS Catalog accession numbers
140 ranging from [GCST90301941 to GCST90302173](#). This comprehensive study identified
141 genetic associations for 233 circulating metabolic traits across 33 cohorts, encompassing
142 a total of 136,016 participants, predominantly of European ancestry, with a small
143 proportion from Asia (11.60%, 15775/136016).

144 Data on Childhood with obesity were contributed by the EGG consortium and
145 downloaded from <http://egg-consortium.org/childhood-obesity-2019.html>.²⁹ To identify
146 genetic variants associated with obesity in children, the researchers conducted a trans-
147 ancestral meta-analysis of 30 studies, which included up to 13,005 cases and 15,599
148 controls from European, African, North American, South American, and East Asian
149 ancestries. Following the screening, GWAS data specific to the European population
150 were extracted for analysis.

151 2.3 Selection of IVs and data harmonization

152 To adhere to the stringent criteria based on the three principal MR assumptions and to
153 mitigate horizontal pleiotropy, only independent genome-wide significant single
154 nucleotide polymorphisms (SNPs) were employed as instrumental variables (IVs) for the
155 exposure. The IVs must be closely related to the exposure (gut microbiota, blood
156 metabolites, Childhood with obesity), and SNPs significantly associated with the
157 occurrence were selected at the whole-genome level ($P < 5 \times 10^{-8}$, $r^2 < 0.001$, window
158 size=10kb). If there are too few SNPs Included, the inclusion criteria can be changed to
159 ($P < 5 \times 10^{-5}$ or $P < 1 \times 10^{-5}$, $r^2 < 0.001$, window size=10kb). Additionally, we calculated the F
160 statistics of the IVs to assess the extent of weak instrument bias. To reduce the bias
161 caused by weak working variables, the working variables with $F > 10$ are retained. The
162 formula for calculating the F value and R^2 is as follows.

$$163 R^2 = 2 \times \beta_{exp}^2 \times eaf_{exp} (1 - eaf_{exp}) / [2 \times \beta_{exp}^2 \times eaf_{exp} \times (1 - eaf_{exp}) + 2 \times n_{exp} \times eaf_{exp} \times (1 - eaf_{exp}) \times se_{exp}^2],$$
$$164 F = R^2 \times [n_{exp} - 2] / (1 - R^2).$$

165 Finally, after data filtering, horizontal pleiotropy analysis was conducted. If there is
166 horizontal pleiotropy, the MR-PRESSO test is performed. The outliers obtained from the
167 test were removed before proceeding with further analysis.

168 2.4 Causal effects of gut microbiota on Childhood with obesity

169 We performed bidirectional MR analyses to investigate the causal relationship between
170 gut microbiota and Childhood with obesity, estimating the total effect (β) of this
171 relationship. We used the inverse variance weighted (IVW) method to estimate effects,
172 reporting $\beta \pm SE$ for continuous outcomes and OR (95%CI) for binary outcomes. In brief,
173 the IVW method meta-analyzed SNP-specific Wald estimates by dividing the SNP-
174 outcome association by the SNP-exposure association, using random effects to derive
175 the final causal effect estimate. Additionally, we used MR-Egger and weighted median
176 methods as complementary approaches to IVW, providing a more comprehensive
177 understanding of the causal relationship.

178 **2.5 Mediation analyses link “gut microbiota–blood metabolite–Childhood with** 179 **obesity”**

180 We further performed a mediation analysis using a two-step MR study to explore whether
181 blood metabolite mediate the causal gut microbiota to Childhood with obesity.³⁰ The
182 specific approach is: (step 1) a two-sample MR (TSMR) model was carried out to
183 estimate the effect of the exposure on the mediator, and (step 2) a second model
184 estimating the effect of each mediator on the outcome was carried out using MVMR. Both
185 the genetic variants for the mediator and the exposure were included in the first and
186 second-stage regressions in MVMR. Using MVMR ensures that the mediator's effect on
187 the outcome is independent of the exposure. Additionally, this method provides an
188 estimate of the direct effect of the exposure on the outcome. The two regression
189 estimates from the second stage regression are multiplied together to estimate the
190 indirect effect^{Error! Bookmark not defined.}.

191 With respect to our research, the overall effect can be decomposed into a direct
192 effect (without mediators) and an indirect effect (through mediators). The total effect of
193 gut microbiota on Childhood with obesity was decomposed: direct effects of gut
194 microbiota on Childhood with obesity (overall effect) and indirect effects mediated by gut
195 microbiota through the blood metabolite (mediation effect). The mediation effect was
196 calculated through $\beta_1 \times \beta_2$: (i) the causal effect of the mediator (blood metabolite) on the
197 outcome (Childhood with obesity) adjusted for exposure-induced confounding (β_2) and (ii)
198 the causal effect of the exposure (gut microbiota) on the mediator (β_1). We calculated the
199 percentage mediated by the mediating effect by dividing the indirect effect by the total
200 effect. Meanwhile, 95%CI was calculated using the delta or difference method.

201 **2.6 Sensitivity analysis**

202 The directional association between each identified SNP and both the exposure and
203 outcome variables was assessed using MR Steiger filtering. This method measures the
204 degree to which the variation in exposure and outcomes can be attributed to instrumental
205 SNPs and determines if the variability in outcomes is less than that in exposure.
206 Horizontal pleiotropy was further investigated via the MR-Egger approach, which utilizes
207 weighted linear regression with an unconstrained intercept. This intercept acts as an
208 indicator of the average pleiotropic effect across genetic variations, reflecting the typical
209 direct influence of a variant on the outcome variable. If the intercept significantly deviated
210 from zero (MR-Egger intercept $P < 0.05$), it indicated the presence of horizontal pleiotropy.
211 Moreover, Cochran's Q-test was used to assess heterogeneity, with lower p-values

212 suggesting increased heterogeneity and a higher probability of directional pleiotropy.
213 Leave-one-out analyses were also performed to identify potential SNP outliers.

214 **2.7 Statistical analysis**

215 We first used the results calculated by the IVW method as the final main result, and a
216 significance threshold of $P < 0.05$ was applied to the MR analysis, where P-values below
217 this threshold were considered statistically significant. All statistical analyses and data
218 visualizations were performed using R software (R Foundation, Vienna, Austria), with the
219 TwoSampleMR (<https://github.com/MRCIEU/TwoSampleMR>) package for 2SMR and
220 MVMR analysis and the PNG (Boutell, Netherlands) package for data visualization.

221 **3 RESULTS**

222 **3.1 Selection of IVs**

223 After screening, there were 13 different types of gut microbiota and 12 different types of
224 blood metabolites with potential causal relationships with Childhood with obesity. The F-
225 statistics for all IVs were above 10, indicating no evidence of weak instrument bias.³¹
226 After the Bonferroni adjustment, the p-values were all below the Bonferroni threshold.

227 **3.2 Causal association between gut microbiota and Childhood with obesity**

228 When evaluating the causal association of gut microbiota with Childhood with obesity, 13
229 types of gut microbiota show potential causal relationships. Relevant details can be found
230 in **Supplementary Table S2**. Among them, the abundances in stool of SM23-33
231 ($OR=0.755$; $95\%CI=0.599-0.951$; $p=0.017$), TMED109 ($OR=0.793$; $95\%CI=0.654-0.961$;
232 $p=0.018$), Eubacterium I ramulus A ($OR=0.846$; $95\%CI=0.743-0.963$; $p=0.011$), K10
233 sp001941205 ($OR=0.895$; $95\%CI=0.805-0.997$; $p=0.043$), Coprobacillus ($OR=0.901$;
234 $95\%CI=0.822-0.987$; $p=0.025$), Ruminococcus E sp900314705 ($OR=0.913$;
235 $95\%CI=0.836-0.998$; $p=0.046$), UBA1206 sp000433115 ($OR=0.926$; $95\%CI=0.859-0.998$;
236 $p=0.043$), and Bacteroides A ($OR=0.932$; $95\%CI=0.873-0.994$; $p=0.033$) show a negative
237 association with Childhood with obesity. This indicates that an increase in the abundance
238 of these microbes leads to a decreased risk of Childhood with obesity.

239 Conversely, the following types of gut microbiota show a positive association with
240 Childhood with obesity: Clostridium saudiense ($OR=1.084$; $95\%CI=1.010-1.163$;
241 $p=0.025$), An181 ($OR=1.151$; $95\%CI=1.013-1.307$; $p=0.030$), Faecalicatena
242 sp001517425 ($OR=1.242$; $95\%CI=1.053-1.465$; $p=0.010$), CAG-698 ($OR=1.250$;
243 $95\%CI=1.091-1.433$; $p=0.001$), UBA8621 ($OR=1.254$; $95\%CI=1.022-1.538$; $p=0.030$),
244 and Halomonadaceae ($OR=1.499$; $95\%CI=1.005-2.236$; $p=0.047$).

245 When evaluating the causal effects of Childhood with obesity on the gut microbiota,
246 it was observed that all p-values were greater than 0.05, suggesting that Childhood with
247 obesity does not have an effect on the gut microbiota under consideration. The relevant
248 details are presented in **Supplementary Table S3**. The final analysis reveals potential
249 causal relationships between 13 types of gut microbiota and Childhood with obesity, as
250 illustrated in **Figure 2**.

251 **3.3 Causal association between blood metabolite and Childhood with obesity**

252 When evaluating the causal association of gut microbiota with Childhood with obesity, 12
253 types of blood metabolites show potential causal relationships. Relevant details are

254 provided in [Supplementary Table S4](#). Among them, the Triglycerides to total lipids ratio in
255 medium VLDL shows a positive association with Childhood with obesity, indicating that
256 an increase in Triglycerides to total lipids ratio in medium VLDL would lead to an
257 increased risk of Childhood with obesity.

258 The other types of blood metabolites show a negative correlation. The IVW analysis
259 results for these seven types of circulating immune cells are: Albumin levels($OR=0.717$;
260 $95\%CI=0.524-0.981$; $p=0.037$), Ratio of 22:6 docosahexaenoic acid to total fatty
261 acids($OR=0.806$; $95\%CI=0.672-0.967$; $p=0.020$), Total cholesterol levels in small
262 HDL($OR=0.842$; $95\%CI=0.714-0.993$; $p=0.041$), Cholesteryl esters to total lipids ratio in
263 small HDL($OR=0.863$; $95\%CI=0.774-0.962$; $p=0.008$), Total cholesterol to total lipids ratio
264 in medium VLDL($OR=0.879$; $95\%CI=0.781-0.989$; $p=0.033$), Total cholesterol to total
265 lipids ratio in small HDL($OR=0.882$; $95\%CI=0.795-0.980$; $p=0.019$), Omega-6 fatty acids
266 levels($OR=0.883$; $95\%CI=0.790-0.986$; $p=0.028$), Total lipids in IDL($OR=0.894$;
267 $95\%CI=0.812-0.984$; $p=0.022$), Total cholesterol to total lipids ratio in large
268 LDL($OR=0.895$; $95\%CI=0.810-0.989$; $p=0.029$), Phospholipids in very small
269 VLDL($OR=0.900$; $95\%CI=0.824-0.984$; $p=0.021$), Cholesteryl esters to total lipids ratio in
270 small LDL($OR=0.902$; $95\%CI=0.817-0.996$; $p=0.042$).

271 When evaluating the causal effects of Childhood with obesity on the blood
272 metabolite, it was observed that all p-values were greater than 0.05, suggesting that
273 Childhood with obesity does not have an effect on the gut microbiota under consideration.
274 The relevant details are provided in [Supplementary Table S5](#). The final analysis reveals
275 potential causal relationships between 12 types of blood metabolites and Childhood with
276 obesity, as illustrated in [Figure 3](#).

277 **3.4 Mediation MR analyses of blood metabolite**

278 In the 2SMR analysis, 13 types of gut microbiota and 12 types of blood metabolites were
279 found to be causally associated with Childhood with obesity, of which the abundance of
280 K10 sp001941205 in stool was significantly associated with the Total cholesterol to total
281 lipids ratio in medium VLDL. Similarly, the abundance of SM23-33 in stool was
282 significantly associated with the ratio of 22:6 docosahexaenoic acid to total fatty acids.
283 The results are presented in [Table 1](#). According to all five methods, genetically predicted
284 K10 sp001941205 abundance in stool was positively associated with the total cholesterol
285 to total lipids ratio in medium VLDL (MR Egger; $OR=1.010$; $95\%CI=0.966-1.057$; $p=0.654$,
286 Weighted median; $OR=1.012$; $95\%CI=0.983-1.042$; $p=0.429$, IVW; $OR=1.024$;
287 $95\%CI=1.003-1.045$; $p=0.024$, Simple mode; $OR=1.011$; $95\%CI=0.946-1.080$; $p=0.754$,
288 Weighted mode; $OR=1.008$; $95\%CI=0.943-1.077$; $p=0.818$). According to IVW methods,
289 genetically predicted SM23-33 abundance in stool was positively associated with the
290 ratio of 22:6 docosahexaenoic acid to total fatty acids (IVW; $OR=1.059$; $95\%CI=1.013-$
291 1.108 ; $p=0.012$).

292 When evaluating the causal effects of blood metabolites on gut microbiota, it was
293 observed that all p-values were greater than 0.05, suggesting that blood metabolites do
294 not have an effect on the gut microbiota under consideration. The relevant details are
295 provided in [Supplementary Table S6](#).

296 We found that the abundance of K10 sp001941205 in stool was associated with an
297 increased Total cholesterol to total lipids ratio in medium VLDL, and this increased ratio
298 was associated with a decreased risk of Childhood with obesity. Our study showed that
299 the Total cholesterol to total lipids ratio in medium VLDL accounted for 2.53% (95%CI;
300 2.14%-2.92%) of the decreased risk associated with K10 sp001941205 abundance in
301 stool concerning Total cholesterol to total lipids ratio in medium VLDL and Childhood with
302 obesity. These results preliminarily illustrate that K10 sp001941205 abundance in stool
303 may reduce the risk of Childhood with obesity partially by enhancing the effects of the
304 Total cholesterol to total lipids ratio in medium VLDL on Childhood with obesity.

305 In addition to these findings, we observed a consistent relationship among SM23-33
306 abundance in stool, the Ratio of 22:6 docosahexaenoic acid to total fatty acids, and
307 Childhood with obesity. Unlike the previous association, the mediation effect of the Ratio
308 of 22:6 docosahexaenoic acid to total fatty acids accounted for 4.07% (95%CI; 2.70%-
309 5.44%). The results are presented in [Figure 4](#). The details of the MVMR analysis are
310 presented in [Supplementary Table S7](#).

311 **3.5 Sensitivity analysis**

312 To address potential pleiotropy in our causal effect estimates, we performed multiple
313 sensitivity analyses. Cochran's Q-test and funnel plot analysis revealed no evidence of
314 heterogeneity or asymmetry among the SNPs involved in the causal relationship, except
315 for CAG-698 abundance in stool on Childhood with obesity (MR Egger $Q=27.222$; $df=16$;
316 $p=0.039$, IVW $Q=91.193$; $df=69$; $p=0.038$) and Ratio of 22:6 docosahexaenoic acid to
317 total fatty acids on Childhood with obesity (MR Egger $Q=91.186$; $df=68$; $p=0.032$).
318 Furthermore, leave-one-out analysis validated the impact of each SNP on the overall
319 causal estimates. Moreover, re-analysis of the MR study after excluding individual SNPs
320 consistently yielded similar results, indicating that all SNPs contributed significantly to the
321 establishment of the causal relationship, with relevant details provided in [Supplementary](#)
322 [Table S8](#).

323 **4 Discussion**

324 In the present study, we investigated the causal association among 473 gut microbiota
325 phenotypes, 233 blood metabolites, and Childhood with obesity using large-scale genetic
326 data and MR analysis. To our knowledge, this is the first MR analysis to explore the
327 causal relationships among various gut microbiota phenotypes, blood metabolites, and
328 Childhood with obesity. Through stringent inclusion criteria and sensitivity analyses, we
329 have identified potential causal links between 13 distinct gut microbiota types and
330 Childhood with obesity, with 2 specific blood metabolites potentially serving as mediators
331 in this pathway.

332 Our study highlights significant associations between various types of gut microbiota
333 and Childhood with obesity, contributing to the body of evidence regarding the role of the
334 gut microbiome in Childhood with obesity. We identified 13 gut microbiota species with
335 potential causal relationships to Childhood with obesity, which opens avenues for further
336 exploration. Several taxa exhibited negative associations with Childhood with obesity. S
337 Specifically, higher abundances in the stool of SM23-33, TMED109, Eubacterium I
338 ramulus A, K10 sp001941205, Coprobacillus, Ruminococcus E sp900314705, UBA1206

339 sp000433115, and Bacteroides A were linked to a reduced risk of Childhood with obesity.
340 This is consistent with findings from previous studies,³²⁻³³ which emphasized the
341 protective role of specific gut microbiota against metabolic diseases by promoting short-
342 chain fatty acid production and enhancing gut barrier integrity.³⁴ These microbes may
343 play a protective role in Childhood with obesity, possibly through mechanisms such as
344 improved metabolic regulation and enhanced satiety signaling.³⁵ Furthermore, a
345 systematic review suggests that a diverse gut microbiota rich in beneficial species can
346 offer resilience against obesity, further reinforcing our findings about the protective
347 implications of specific bacterial populations³⁶. Conversely, certain taxa demonstrated
348 positive associations with Childhood with obesity, including Clostridium saudiense, An181,
349 Faecalicatena sp001517425, CAG-698, UBA8621, and Halomonadaceae. These findings
350 align with previous research, which identified that increased abundances of specific
351 harmful bacteria could contribute to inflammation and insulin resistance, subsequently
352 leading to obesity.³⁷ The role of these microbes in promoting obesity raises important
353 questions regarding their mechanisms, which may involve inflammatory pathways and
354 metabolic disruption.³⁸⁻³⁹ Our results emphasize the necessity of understanding the
355 complex interplay between gut microbiota and host metabolism, encouraging future
356 research to delve deeper into these relationships. Longitudinal studies that explore shifts
357 in gut microbiota composition throughout childhood, as well as interventional studies
358 targeting specific microbiota, will be crucial. These investigations could help identify
359 effective strategies for obesity prevention and management through microbiota
360 modulation. Recognizing these microbial profiles could inform future therapeutic
361 strategies targeting gut health to combat the growing challenge of Childhood with obesity.

362 This study provides important insights into the causal relationships between gut
363 microbiome-associated blood metabolites and Childhood with obesity. Using Mendelian
364 randomization analysis, we identified 12 types of blood metabolites that show potential
365 causal associations with the risk of Childhood with obesity. Notably, the Triglycerides to
366 total lipids ratio in medium VLDL exhibited a positive causal relationship with Childhood
367 with obesity. This indicates that an increase in this ratio would lead to an elevated risk of
368 Childhood with obesity. This finding is consistent with previous evidence suggesting that
369 higher triglyceride levels in VLDL are associated with an increased risk of obesity and
370 metabolic disorders. In contrast, the other 11 blood metabolites showed inverse causal
371 relationships with Childhood with obesity risk. These include Albumin levels, the Ratio of
372 22:6 docosahexaenoic acid (DHA) to total fatty acids, Total cholesterol levels in small
373 HDL, Cholesteryl esters to total lipids ratio in small HDL, Total cholesterol to total lipids
374 ratio in medium VLDL, Total cholesterol to total lipids ratio in small HDL, Omega-6 fatty
375 acid levels, Total lipids in IDL, Total cholesterol to total lipids ratio in large LDL,
376 Phospholipids in very small VLDL, and Cholesteryl esters to total lipids ratio in small LDL.
377 These inverse causal associations suggest that higher levels or ratios of these
378 metabolites may confer a protective effect against Childhood with obesity. For instance,
379 the beneficial effects of DHA and omega-6 fatty acids on metabolic health and obesity
380 risk have been well-documented.⁴⁰⁻⁴¹ Additionally, the ratios of cholesterol to total lipids in
381 various lipoprotein fractions may reflect favorable lipid profiles associated with a lower
382 obesity risk.

383 This study has identified a significant relationship between the abundance of the gut
384 microbiome species K10 sp001941205 and Total cholesterol to total lipids ratio in
385 medium VLDL. Our findings indicate that this VLDL ratio can account for approximately
386 2.53% (95%CI; 2.14%-2.92%) of the decline in obesity risk associated with the
387 abundance of K10 sp001941205. This suggests that K10 sp001941205 may partially
388 reduce the risk of Childhood with obesity by enhancing the effects of the VLDL
389 cholesterol to lipid ratio. Additionally, we observed a consistent association between the
390 abundance of SM23-33, Ratio of 22:6 docosahexaenoic acid to total fatty acids, and
391 Childhood with obesity. Unlike the prior relationship, the mediation effect of the DHA ratio
392 accounted for 4.07% (95%CI; 2.70%-5.44%) of the decrease in Childhood with obesity
393 risk. These findings enrich current literature by highlighting the role of gut microbiota in
394 modulating lipid metabolism, which in turn influences obesity risk in children. Previous
395 studies have suggested a negative relationship between triglycerides in VLDL and
396 obesity risk.⁴² Conversely, our findings, suggest that an elevated VLDL cholesterol to lipid
397 ratio may provide a protective effect, potentially due to the complex interrelations
398 between these lipid components and obesity. Furthermore, increased DHA intake and its
399 ratio to total fatty acids have been linked to improved metabolic health and a lower risk of
400 obesity,⁴³⁻⁴⁴ aligning with our observations. These results indicate that gut microbiota may
401 influence metabolic health and obesity outcomes by modulating specific blood
402 metabolites. This microbiome-host interaction appears to be a complex dynamic process
403 involving multiple mechanisms.⁴⁵ Future research should delve deeper into how these
404 key microbial species regulate lipid metabolism, potentially offering new targets for
405 preventing and treating Childhood with obesity. Moreover, considering the high individual
406 variability in metabolite and microbiome interactions, targeted interventions will be
407 critical.⁴⁶⁻⁴⁷ In conclusion, this study highlights the complex association between specific
408 gut bacteria, their metabolites, and the risk of Childhood with obesity. These insights
409 provide a new perspective for understanding the mechanisms underlying metabolic
410 diseases in children and lay a foundation for developing future prevention and treatment
411 strategies. The identification of these causal relationships between gut microbiome-
412 related blood metabolites and Childhood with obesity provides valuable insights into the
413 underlying mechanisms. It highlights the complex interplay between the gut microbiome,
414 lipid metabolism, and obesity development. These findings suggest that targeting specific
415 microbial signatures and their associated metabolic pathways may offer promising
416 avenues for the prevention and management of Childhood with obesity. Future research
417 should further elucidate the precise biological mechanisms by which these gut
418 microbiome-derived metabolites influence obesity risk. Additionally, exploring the
419 potential for personalized interventions that modulate the gut microbiome and its
420 metabolic outputs could lead to more effective strategies for tackling the Childhood with
421 obesity epidemic. In conclusion, this study has uncovered compelling causal evidence
422 linking gut microbiome-associated blood metabolites to the risk of Childhood with obesity.
423 These insights pave the way for developing novel, microbiome-based approaches to
424 address this pressing public health challenge.

425 The present study has several strengths that can guide future directions in
426 Childhood with obesity research. First, our work comprises the first systematic

427 investigation to examine the causal relationship between gut microbiota, blood
428 metabolites, and Childhood with obesity. This unique contribution is underscored by the
429 comprehensive analysis of 473 distinct types of gut microbiota and 233 blood metabolites.
430 By using an MR design, the study effectively mitigated issues related to reverse causality
431 and residual confounding variables.⁴⁸ Furthermore, thorough sensitivity analyses were
432 conducted to eliminate the potential influence of genetic polymorphisms, thereby
433 enhancing the validity of the causal inferences drawn from the study. Second, compared
434 with conventional ideas of studying gut microbiota and metabolites within the Childhood
435 with obesity microenvironment, our study aimed to examine the causal relationship
436 between gut microbiota, blood metabolites and Childhood with obesity. Our findings
437 underscore the potential impact of gut microbiota and metabolites in peripheral blood on
438 the progression of Childhood with obesity, shedding light on their role in the onset and
439 advancement of the disease. Third, we have identified a set of gut microbiota and blood
440 metabolites that exhibit a strong correlation with the risk of Childhood with obesity. These
441 findings present potential biomarkers for non-invasive stool testing in Childhood with
442 obesity that warrant validation through subsequent experiments. Finally, we have
443 proposed a potential axis of K10 sp001941205–Total cholesterol to total lipids ratio in
444 medium VLDL–Childhood with obesity, as well as another axis SM23-33–Ratio of 22:6
445 docosahexaenoic acid to total fatty acids–Childhood with obesity, which may serve as a
446 foundation for drug development strategies in Childhood with obesity research. Further
447 investigation utilizing in vitro and in vivo models is necessary to validate these proposed
448 axes and to develop targeted therapies accordingly.

449 The present study performed a two-sample, bidirectional, multivariable, and two-step
450 mediation MR analysis utilizing large genome-wide association study datasets,
451 demonstrating high statistical efficiency. The conclusions drawn in our study are
452 grounded in genetic IVs, with causal inference conducted through multiple MR analysis
453 methods. The findings are robust and unaffected by horizontal pleiotropy and other
454 confounding factors. Meanwhile, our study also has several limitations. First, our analysis
455 was performed using the European population, which limits its application in all people
456 worldwide. Second, the dataset on Childhood with obesity is general and lacks subtype
457 information, which may not accurately reflect the characteristics of specific subtypes
458 within Childhood with obesity. Third, despite efforts to detect and remove outlier variants,
459 the potential influence of horizontal pleiotropy on our findings cannot be completely ruled
460 out. Additionally, the utilization of summary-level statistics rather than individual-level data
461 in our analysis limits our ability to investigate causal relationships within specific
462 subgroups, such as females and males. Finally, our research indicates a modest genetic
463 prediction of Childhood with obesity, mediated by the total cholesterol to total lipids ratio
464 in medium VLDL at 2.53% (95%CI; 2.14%-2.92%) and the ratio of 22:6 docosahexaenoic
465 acid to total fatty acids at 4.07% (95%CI; 2.70%-5.44%), suggesting the need for further
466 investigation into additional mediators.

467 **Authors Contributions**

468 Min Zhang conceived and designed the study, conducted data analysis and interpretation,
469 and wrote the manuscript. Wenjuan Yan developed the research hypothesis.

470 **Funding**

471 This work was supported by Shanghai Pudong New District Health Commission Health
472 Science and Technology Project (Grant numbers PW2021A-76).

473 **Competing Interests**

474 The author declares no competing interests related to this research.

475 **Availability of Data and Materials**

476 The analysis utilized publicly available datasets. Detailed information on all original
477 contributions can be found in the "Data Sources" section, including specific download
478 links and accession numbers. Readers can refer to this section for access. For further
479 inquiries, please contact the corresponding author.

480 **Conflict of Interest**

481 The authors declare that they have no conflict of interest.

482 **References**

- 1 Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2014 Aug 30;384(9945):766-81. doi: 10.1016/S0140-6736(14)60460-8. Epub 2014 May 29. Erratum in: *Lancet*. 2014 Aug 30;384(9945):746. PMID: 24880830; PMCID: PMC4624264.
- 2 Vajravelu M E, Tas E, Arslanian S. Pediatric obesity: complications and current day management[J]. *Life*, 2023, 13(7): 1591.
- 3 Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. *J Epidemiol Glob Health*. 2020 Mar;10(1):107-111. doi: 10.2991/jegh.k.191028.001. PMID: 32175717; PMCID: PMC7310804.
- 4 Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele CE, Neeland IJ, Sanders P, St-Onge MP; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Circulation*. 2021 May 25;143(21):e984-e1010. doi: 10.1161/CIR.0000000000000973. Epub 2021 Apr 22. PMID: 33882682; PMCID: PMC8493650.
- 5 Mitra AT, Das B, Sarraf KM, Ford-Adams M, Fehervari M, Ashrafian H. Bone health following paediatric and adolescent bariatric surgery: a systematic review and meta-analysis. *EClinicalMedicine*. 2024 Feb 2;69:102462. doi: 10.1016/j.eclinm.2024.102462. PMID: 38333369; PMCID: PMC10850131.
- 6 Cannarella R, Caruso M, Condorelli RA, Timpanaro TA, Caruso MA, La Vignera S, Calogero AE. Testicular volume in 268 children and adolescents followed-up for childhood obesity-a retrospective cross-sectional study. *Eur J Endocrinol*. 2023 Apr 5;188(4):331-342. doi: 10.1093/ajendo/lvad033. PMID: 37127298.
- 7 Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K; International Agency for Research on Cancer Handbook Working Group. Body Fatness and Cancer--Viewpoint of the IARC Working Group. *N Engl J Med*. 2016 Aug 25;375(8):794-8. doi: 10.1056/NEJMs1606602. PMID: 27557308; PMCID: PMC6754861.
- 8 Zarpellon RSM, Vilela DRM, Louzada FM, Radominski DRB, Crippa DACS. Association of food intake with sleep disorders in children and adolescents with obesity. *Sleep Med X*. 2022 Aug 23;4:100053. doi: 10.1016/j.sleepx.2022.100053. PMID: 36072436;

- PMCID: PMC9442327.
- 9 Okunogbe A, Nugent R, Spencer G, Powis J, Ralston J, Wilding J. Economic impacts of overweight and obesity: current and future estimates for 161 countries. *BMJ Glob Health*. 2022 Sep;7(9):e009773. doi: 10.1136/bmjgh-2022-009773. PMID: 36130777; PMCID: PMC9494015.
 - 10 Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, Tuohy K. Gut microbiota functions: metabolism of nutrients and other food components. *Eur J Nutr*. 2018 Feb;57(1):1-24. doi: 10.1007/s00394-017-1445-8. Epub 2017 Apr 9. PMID: 28393285; PMCID: PMC5847071.
 - 11 Quigley EM. Gut bacteria in health and disease. *Gastroenterol Hepatol (N Y)*. 2013 Sep;9(9):560-9. PMID: 24729765; PMCID: PMC3983973.
 - 12 Suez J, Elinav E. The path towards microbiome-based metabolite treatment. *Nat Microbiol*. 2017 May 25;2:17075. doi: 10.1038/nmicrobiol.2017.75. PMID: 28540921.
 - 13 Wolff R, Shoemaker W, Garud N. Ecological Stability Emerges at the Level of Strains in the Human Gut Microbiome. *mBio*. 2023 Apr 25;14(2):e0250222. doi: 10.1128/mbio.02502-22. Epub 2023 Feb 21. PMID: 36809109; PMCID: PMC10127601.
 - 14 Grigorescu I, Dumitrascu DL. IMPLICATION OF GUT MICROBIOTA IN DIABETES MELLITUS AND OBESITY. *Acta Endocrinol (Buchar)*. 2016 Apr-Jun;12(2):206-214. doi: 10.4183/aeb.2016.206. PMID: 31149088; PMCID: PMC6535288.
 - 15 Indiani CMDSP, Rizzardi KF, Castelo PM, Ferraz LFC, Darrieux M, Parisotto TM. Childhood Obesity and Firmicutes/Bacteroidetes Ratio in the Gut Microbiota: A Systematic Review. *Child Obes*. 2018 Nov/Dec;14(8):501-509. doi: 10.1089/chi.2018.0040. Epub 2018 Sep 5. PMID: 30183336.
 - 16 Kasubuchi M, Hasegawa S, Hiramatsu T, Ichimura A, Kimura I. Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. *Nutrients*. 2015 Apr 14;7(4):2839-49. doi: 10.3390/nu7042839. PMID: 25875123; PMCID: PMC4425176.
 - 17 Doğan D, Çelik T. Research trends on the gut microbiota in endocrine metabolism: a thematic and bibliometric analysis. *Front Cell Infect Microbiol*. 2024 Mar 22;14:1371727. doi: 10.3389/fcimb.2024.1371727. PMID: 38585653; PMCID: PMC10995354.
 - 18 Zmora N, Suez J, Elinav E. You are what you eat: diet, health and the gut microbiota. *Nat Rev Gastroenterol Hepatol*. 2019 Jan;16(1):35-56. doi: 10.1038/s41575-018-0061-2. PMID: 30262901.
 - 19 Nicolucci AC, Hume MP, Martínez I, Mayengbam S, Walter J, Reimer RA. Prebiotics Reduce Body Fat and Alter Intestinal Microbiota in Children Who Are Overweight or With Obesity. *Gastroenterology*. 2017 Sep;153(3):711-722. doi: 10.1053/j.gastro.2017.05.055. Epub 2017 Jun 5. PMID: 28596023.
 - 20 Cho KY. Association of gut microbiota with obesity in children and adolescents. *Clin Exp Pediatr*. 2023 Apr;66(4):148-154. doi: 10.3345/cep.2021.01837. Epub 2022 Nov 16. PMID: 36397257; PMCID: PMC10080385.
 - 21 Vallianou N, Stratigou T, Christodoulatos GS, Dalamaga M. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives. *Curr Obes Rep*. 2019 Sep;8(3):317-332. doi: 10.1007/s13679-019-00352-2. PMID: 31175629.
 - 22 Zhernakova A, Kurilshikov A, Bonder MJ, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. *Science*. 2016 Apr 29;352(6285):565-9. doi: 10.1126/science.aad3369. Epub 2016 Apr 28. PMID: 27126040; PMCID: PMC5240844.
 - 23 Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, Langdon R, Tan VY, Yarmolinsky J, Shihab HA, Timpson NJ, Evans DM, Relton C, Martin RM, Davey Smith G, Gaunt TR, Haycock PC. The MR-Base platform supports systematic causal inference across the human phenome. *Elife*. 2018 May 30;7:e34408. doi: 10.7554/eLife.34408. PMID: 29846171; PMCID: PMC5976434.
 - 24 Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in

- epidemiology. *Stat Med*. 2008 Apr 15;27(8):1133-63. doi: 10.1002/sim.3034. PMID: 17886233.
- 25 Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum Mol Genet*. 2014 Sep 15;23(R1):R89-98. doi: 10.1093/hmg/ddu328. Epub 2014 Jul 4. PMID: 25064373; PMCID: PMC4170722.
- 26 Skvanková VW, Richmond RC, Woolf BAR, et al. Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. *JAMA*. 2021 Oct 26;326(16):1614-1621. doi: 10.1001/jama.2021.18236. PMID: 34698778.
- 27 Qin Y, Havulinna AS, Liu Y, Jousilahti P, Ritchie SC, Tokolyi A, Sanders JG, Valsta L, Brożyńska M, Zhu Q, Tripathi A, Vázquez-Baeza Y, Loomba R, Cheng S, Jain M, Niiranen T, Lahti L, Knight R, Salomaa V, Inouye M, Méric G. Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort. *Nat Genet*. 2022 Feb;54(2):134-142. doi: 10.1038/s41588-021-00991-z. Epub 2022 Feb 3. Erratum in: *Nat Genet*. 2024 Mar;56(3):554. doi: 10.1038/s41588-024-01693-y. PMID: 35115689; PMCID: PMC9883041.
- 28 Karjalainen MK, Karthikeyan S, Oliver-Williams C, Sliz E, Allara E, et al. Genome-wide characterization of circulating metabolic biomarkers. *Nature*. 2024 Apr;628(8006):130-138. doi: 10.1038/s41586-024-07148-y. Epub 2024 Mar 6. PMID: 38448586; PMCID: PMC10990933.
- 29 Bradfield JP, Vogelesang S, Felix JF, et al. A trans-ancestral meta-analysis of genome-wide association studies reveals loci associated with childhood obesity. *Hum Mol Genet*. 2019 Oct 1;28(19):3327-3338. doi: 10.1093/hmg/ddz161. PMID: 31504550; PMCID: PMC6859434.
- 30 Burgess S, Daniel RM, Butterworth AS, Thompson SG; EPIC-InterAct Consortium. Network Mendelian randomization: using genetic variants as instrumental variables to investigate mediation in causal pathways. *Int J Epidemiol*. 2015 Apr;44(2):484-95. doi: 10.1093/ije/dyu176. Epub 2014 Aug 22. PMID: 25150977; PMCID: PMC4469795.
- 31 Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. *Stat Methods Med Res*. 2017 Oct;26(5):2333-2355. doi: 10.1177/0962280215597579. Epub 2015 Aug 17. PMID: 26282889; PMCID: PMC5642006.
- 32 Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto JM, Kennedy S, Leonard P, Li J, Burgdorf K, Grarup N, Jørgensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S, Zoetendal EG, Brunak S, Clément K, Doré J, Kleerebezem M, Kristiansen K, Renault P, Sicheritz-Ponten T, de Vos WM, Zucker JD, Raes J, Hansen T; MetaHIT consortium; Bork P, Wang J, Ehrlich SD, Pedersen O. Richness of human gut microbiome correlates with metabolic markers. *Nature*. 2013 Aug 29;500(7464):541-6. doi: 10.1038/nature12506. PMID: 23985870.
- 33 Riva A, Borgo F, Lassandro C, Verduci E, Morace G, Borghi E, Berry D. Pediatric obesity is associated with an altered gut microbiota and discordant shifts in Firmicutes populations. *Environ Microbiol*. 2017 Jan;19(1):95-105. doi: 10.1111/1462-2920.13463. Epub 2016 Aug 22. PMID: 27450202; PMCID: PMC5516186.
- 34 Zhao L, Zhang F, Ding X, Wu G, Lam YY, Wang X, Fu H, Xue X, Lu C, Ma J, Yu L, Xu C, Ren Z, Xu Y, Xu S, Shen H, Zhu X, Shi Y, Shen Q, Dong W, Liu R, Ling Y, Zeng Y, Wang X, Zhang Q, Wang J, Wang L, Wu Y, Zeng B, Wei H, Zhang M, Peng Y, Zhang C. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. *Science*. 2018 Mar 9;359(6380):1151-1156. doi: 10.1126/science.aao5774. PMID: 29590046.
- 35 Musso G, Gambino R, Cassader M. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. *Annu Rev Med*. 2011;62:361-80. doi: 10.1146/annurev-med-012510-175505. PMID: 21226616.
- 36 Cantón R, De Lucas Ramos P, García-Botella A, García-Lledó A, Hernández-Sampelayo T, Gómez-Pavón J, González Del Castillo J, Martín-Delgado MC, Martín Sánchez FJ, Martínez-Sellés M, Molero García JM, Moreno Guillén S, Rodríguez-Artalejo FJ, Reigadas E, Del Campo R, Serrano S, Ruiz-Galiana J, Bouza E. Human

- intestinal microbiome: Role in health and disease. *Rev Esp Quimioter*. 2024 Jul 9:canton09jul2024. doi: 10.37201/req/056.2024. Epub ahead of print. PMID: 38978509.
- 37 Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. *Nature*. 2006 Dec 21;444(7122):1022-3. doi: 10.1038/4441022a. PMID: 17183309.
- 3838 Cani PD, Everard A. Talking microbes: When gut bacteria interact with diet and host organs. *Mol Nutr Food Res*. 2016 Jan;60(1):58-66. doi: 10.1002/mnfr.201500406. Epub 2015 Aug 26. PMID: 26178924; PMCID: PMC5014210.
- 39 Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. *Cell*. 2016 Jun 2;165(6):1332-1345. doi: 10.1016/j.cell.2016.05.041. PMID: 27259147.
- 40 Martínez-Martínez MI, Alegre-Martínez A, Cauli O. Omega-3 Long-Chain Polyunsaturated Fatty Acids Intake in Children: The Role of Family-Related Social Determinants. *Nutrients*. 2020 Nov 11;12(11):3455. doi: 10.3390/nu12113455. PMID: 33187190; PMCID: PMC7697719.
- 41 Young IE, Parker HM, Cook RL, O'Dwyer NJ, Garg ML, Steinbeck KS, Cheng HL, Donges C, Franklin JL, O'Connor HT. Association between Obesity and Omega-3 Status in Healthy Young Women. *Nutrients*. 2020 May 20;12(5):1480. doi: 10.3390/nu12051480. PMID: 32443667; PMCID: PMC7284478.
- 42 Wang N, Chen M, Fang D. Relationship between serum triglyceride to high-density lipoprotein cholesterol ratio and sarcopenia occurrence rate in community-dwelling Chinese adults. *Lipids Health Dis*. 2020 Dec 4;19(1):248. doi: 10.1186/s12944-020-01422-4. PMID: 33276798; PMCID: PMC7716486.
- 43 Albracht-Schulte K, Kalupahana NS, Ramalingam L, Wang S, Rahman SM, Robert-McComb J, Moustaid-Moussa N. Omega-3 fatty acids in obesity and metabolic syndrome: a mechanistic update. *J Nutr Biochem*. 2018 Aug;58:1-16. doi: 10.1016/j.jnutbio.2018.02.012. Epub 2018 Feb 27. PMID: 29621669; PMCID: PMC7561009.
- 44 Lopez-Huertas E. The effect of EPA and DHA on metabolic syndrome patients: a systematic review of randomised controlled trials. *Br J Nutr*. 2012 Jun;107 Suppl 2:S185-94. doi: 10.1017/S0007114512001572. PMID: 22591892.
- 45 McBurney MI, Davis C, Fraser CM, Schneeman BO, Huttenhower C, Verbeke K, Walter J, Latulippe ME. Establishing What Constitutes a Healthy Human Gut Microbiome: State of the Science, Regulatory Considerations, and Future Directions. *J Nutr*. 2019 Nov 1;149(11):1882-1895. doi: 10.1093/jn/nxz154. PMID: 31373365; PMCID: PMC6825832.
- 46 Visconti A, Le Roy CI, Rosa F, Rossi N, Martin TC, Mohny RP, Li W, de Rinaldis E, Bell JT, Venter JC, Nelson KE, Spector TD, Falchi M. Interplay between the human gut microbiome and host metabolism. *Nat Commun*. 2019 Oct 3;10(1):4505. doi: 10.1038/s41467-019-12476-z. PMID: 31582752; PMCID: PMC6776654.
- 47 David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ. Diet rapidly and reproducibly alters the human gut microbiome. *Nature*. 2014 Jan 23;505(7484):559-63. doi: 10.1038/nature12820. Epub 2013 Dec 11. PMID: 24336217; PMCID: PMC3957428.
- 48 Kim MS, Song M, Shin JI, Won HH. How to interpret studies using Mendelian randomisation. *BMJ Evid Based Med*. 2023 Aug;28(4):251-254. doi: 10.1136/bmjebm-2022-112149. Epub 2023 Feb 8. PMID: 36754584.

Table 1 Causal Effects Between Gut Microbiota, Blood Metabolites and Childhood with obesity

<i>method</i>	<i>n</i>	<i>b</i>	<i>se</i>	<i>p</i>	<i>lo_ci</i>	<i>up_ci</i>	<i>or</i>	<i>or_lci95</i>	<i>or_uci95</i>
K10 sp001941205 abundance in stool on Childhood with obesity									
MR Egger	68	-0.110	0.129	0.400	-0.363	0.144	0.896	0.695	1.155
Weighted median	68	-0.087	0.074	0.239	-0.232	0.058	0.916	0.793	1.060
Inverse variance weighted	68	-0.110	0.055	0.043	-0.217	-0.003	0.895	0.805	0.997
Simple mode	68	-0.041	0.175	0.816	-0.383	0.302	0.960	0.682	1.352
Weighted mode	68	-0.080	0.145	0.581	-0.364	0.203	0.923	0.695	1.225
Total cholesterol to total lipids ratio in medium VLDL on Childhood with obesity									
MR Egger	47	-0.192	0.107	0.080	-0.402	0.018	0.825	0.669	1.019
Weighted median	47	-0.174	0.083	0.037	-0.338	-0.011	0.840	0.713	0.989
Inverse variance weighted	47	-0.129	0.060	0.033	-0.247	-0.011	0.879	0.781	0.989
Simple mode	47	-0.223	0.143	0.126	-0.504	0.057	0.800	0.604	1.059
Weighted mode	47	-0.214	0.085	0.015	-0.380	-0.047	0.807	0.684	0.954
K10 sp001941205 abundance in stool on Total cholesterol to total lipids ratio in medium VLDL									
MR Egger	70	0.010	0.023	0.654	-0.035	0.056	1.010	0.966	1.057
Weighted median	70	0.012	0.015	0.429	-0.017	0.041	1.012	0.983	1.042
Inverse variance weighted	70	0.024	0.011	0.024	0.003	0.044	1.024	1.003	1.045
Simple mode	70	0.011	0.034	0.754	-0.055	0.077	1.011	0.946	1.080
Weighted mode	70	0.008	0.034	0.818	-0.058	0.074	1.008	0.943	1.077
SM23-33 abundance in stool on Childhood with obesity									
MR Egger	71	-0.261	0.304	0.393	-0.857	0.335	0.770	0.425	1.397
Weighted median	71	-0.142	0.169	0.400	-0.473	0.189	0.868	0.623	1.208
Inverse variance weighted	71	-0.282	0.118	0.017	-0.513	-0.050	0.755	0.599	0.951
Simple mode	71	-0.080	0.387	0.837	-0.839	0.679	0.923	0.432	1.972
Weighted mode	71	-0.080	0.342	0.816	-0.751	0.591	0.923	0.472	1.806
Ratio of 22:6 docosahexaenoic acid to total fatty acids on Childhood with obesity									
MR Egger	18	-0.206	0.138	0.155	-0.476	0.065	0.814	0.621	1.067
Weighted median	18	-0.185	0.088	0.035	-0.357	-0.013	0.831	0.700	0.987
Inverse variance weighted	18	-0.215	0.093	0.020	-0.397	-0.033	0.806	0.672	0.967
Simple mode	18	-0.073	0.221	0.744	-0.506	0.359	0.929	0.603	1.432
Weighted mode	18	-0.176	0.081	0.045	-0.336	-0.017	0.838	0.715	0.983
SM23-33 abundance in stool on Ratio of 22:6 docosahexaenoic acid to total fatty acids									
MR Egger	71	0.110	0.053	0.044	0.005	0.215	1.116	1.005	1.239
Weighted median	71	0.055	0.033	0.095	-0.010	0.120	1.057	0.990	1.128
Inverse variance weighted	71	0.057	0.023	0.012	0.012	0.102	1.059	1.013	1.108
Simple mode	71	0.039	0.080	0.627	-0.118	0.197	1.040	0.888	1.218
Weighted mode	71	0.042	0.077	0.589	-0.110	0.194	1.043	0.896	1.214

GWAS Summary Data

Gut microbiota abundance in stool (Exposure)
5,969 Finnish individuals, FINRISK 2002, Qin Y et al. 2022
Childhood obesity (Outcomes)
13005 European individuals, EGG consortium, Bradfield JP et al. 2019
Blood metabolites (Mediator)
136,016 individuals from ALSPAC et al. Karjalainen MK et al. 2024



Data Quality Control

Extracting european population data



Instrumental variables

Single nucleotide polymorphism



Assumption 1

Exposure

Gut microbiota abundance in stool



β_1

Inversive MR analysis

β

Inversive MR analysis

β'

Outcome

Childhood obesity

Inversive MR analysis

β_2

Multivariable Mendelian Randomization

Confoundings

outside factor skews the relationship between exposure and outcome



Selection of genetic IVs

- Associated with gut microbiota abundance in stool ($P < 5 \times 10^{-8}$), blood metabolites ($P < 5 \times 10^{-8}$), childhood obesity ($P < 5 \times 10^{-8}$)
- $LD R^2 < 0.001$, window size=10kb
- Exclude the ambiguous SNPs with non-concordant alleles, palindromic SNPs and SNPs with a minor allele frequency < 0.01
- Remove potential pleiotropic SNPs by MR-PRESSO
- Remove SNPs associated with confounder

Mendelian randomization

- Inverse variance weighted
- MR Egger
- Weighted median
- Simple mode
- Weighted mode

Sensitivity analysis

- Cochran's Q test (Heterogeneity)
- F statistic (Strength of IVs)
- R^2 (The proportion of variance)
- MR-Egger intercept (Pleiotropic test)
- MR-PRESSO (Outlier test)
- Leave-one-out

Two-step MR analysis
Mediation effect = $\beta_1 \beta_2$

Assumption 1: the genetic IVs are strongly associated with exposure

Assumption 2: the genetic IVs are not associated with confounders linked to the selected exposure and outcome

Assumption 3: the genetic IVs influence the outcome only through the exposure

Figure 1. Overall study design plan. GWAS, genome-wide association studies; SNPs: single-nucleotide polymorphisms; β : the total causal effects of exposure on outcome was calculated using 2SMR method; β_1 : the causal effects of exposure on mediators were calculated using 2SMR method; β_2 : the causal effects of mediators on outcome were calculated using MVMR method; β' : the direct causal effects of exposure on outcome were calculated using the formula $\beta' = \beta - (\beta_1 \times \beta_2)$.




Figure 2. Mendelian randomization analyses show causal effects between gut microbiota and childhood with obesity. The forest plot shows significant causal associations with $p < 0.05$ and the estimated odds ratio (OR) with 95% confidence intervals (CI).




Figure 3. Mendelian randomization analyses show causal effects between blood metabolites and childhood with obesity. The forest plot shows significant causal associations with $p < 0.05$ and the estimated odds ratio (OR) with 95% confidence intervals (CI).




Figure 4. Schematic diagram of the mediating effect of blood metabolite between Gut microbiota and Childhood with obesity.